December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Tolerance of Ocular Iontophoresis in Healthy Volunteers
Author Affiliations & Notes
  • TM Parkinson
    Research and Development IOMED Inc Salt Lake City UT
  • E Ferguson
    Simbec Research Ltd Merthyr Tydfil United Kingdom
  • S Febbraro
    Simbec Research Ltd Merthyr Tydfil United Kingdom
  • A Bakhtyari
    Simbec Research Ltd Merthyr Tydfil United Kingdom
  • M Mundasad
    Bristol Eye Hospital Bristol United Kingdom
  • Footnotes
    Commercial Relationships    T.M. Parkinson, Iomed, Inc. E; E. Ferguson, Simbec Research Ltd. E; S. Febbraro, Simbec Research Ltd. E; A. Bakhtyari, Simbec Research Ltd. E; M. Mundasad, Simbec Research Ltd. C.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1854. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      TM Parkinson, E Ferguson, S Febbraro, A Bakhtyari, M Mundasad; Tolerance of Ocular Iontophoresis in Healthy Volunteers . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1854.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Evaluate ocular tolerance of iontophoresis applied to sclera of healthy volunteers using novel hydrogel drug delivery applicators (OcuPhor®) filled with balanced salt solution. Methods: Three-period crossover study in 24 healthy male and female volunteers, 18-43 YO, with visual acuity greater than 20/30. 18 subjects received 0 mA and two of the following iontophoretic currents: 0.1, 0.5, 1, 2, 3, or 4 mA for 20 min; in addition 6 volunteers received 3 mA for 20 min and 0 and 1.5 mA for 40 min. Safety and tolerance were determined by VAS and ophthalmic assessments (slit lamp, visual acuity, funduscopy, tonometry, Ishihara color vision test, and fluorescein staining). Subjects were evaluated before and at intervals up to 24 hr after dosing. Results: OcuPhor applicators were well-tolerated and no clinically significant changes in symptomology or in ophthalmic assessments were seen following exposure to 0-3 mA for 20 min (0-60 mAmin total electric charge). At 4 mA two subjects reported a severe burning sensation under the applicator during dosing; this discomfort persisted for several hours after dosing but resolved by 22 hr post-dose. Some superficial fluorescein staining was observed at 1 hr, but not at 22 hr, post-dose. No further dosing was done at 4 mA. No clinically significant findings were observed following exposure to 1.5 mA for 40 min (60 mAmin total charge). Conclusion: Ocular iontophoresis with the OcuPhor system was safe and well-tolerated at doses as high as 3 mA for 20 min/1.5 mA for 40 min and has promise for noninvasive drug delivery to the eye.

Keywords: 514 pharmacology • 356 clinical (human) or epidemiologic studies: systems/equipment/techniques 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.